Company: MIRA
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001183
Chunk: 48

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 1A
Chunk 48
---
 commercialization thereof, does not and will not infringe any third party’s intellectual
property.

If
we are unable to obtain and maintain intellectual property protection for our technology and products, or if the scope of the intellectual
property protection obtained is not sufficiently broad, our competitors could commercialize technology and products similar or identical
to ours, and our ability to successfully commercialize our technology and products may be impaired.

Our
success depends in large part on our ability to obtain and maintain patent protection in relevant countries with respect to our proprietary
technology and products. We seek to protect our proprietary position by filing patent applications in the United States and internationally
that are related to our novel technologies and product candidates. This patent portfolio includes issued patents and pending patent applications
covering pharmaceutical compositions and methods of use.

The
patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent
applications at a reasonable cost or in a timely manner. We may choose not to seek patent protection for certain innovations and may
choose not to pursue patent protection in certain jurisdictions, and under the laws of certain jurisdictions, patents or other intellectual
property rights may be unavailable or limited in scope. It is also possible that we will fail to identify patentable aspects of our discovery
and nonclinical development output before it is too late to obtain patent protection. Moreover, in some circumstances, we may not have
the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology
that we license from third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent
with the best interests of our business.

49

The
patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions
and has in recent years been the subject of much litigation. In addition, the laws of foreign countries may not protect our rights to
the same extent as the laws of the United States. For example, India and China do not allow patents for methods of treating the human
body. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the
United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore,
we cannot know with certainty whether we were the first to make the inventions claimed in our owned or licensed patents or pending patent
applications, or that we were the first to file for patent protection of such